Lung Cancer

IASLC 2017: First-Line Pembrolizumab Increases Overall Survival vs Chemotherapy in Metastatic NSCLC With High Levels of PD-L1

Updated overall survival findings from the phase III KEYNOTE-024 trial evaluating pembrolizumab (Keytruda) as a first-line monotherapy in patients with non–small cell lung cancer (NSCLC) whose tumors express high levels of programmed cell death ligand 1 (PD-L1) were presented at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) in Yokohama, Japan.

Colorectal Cancer

Immunotherapy for Metastatic Mismatch Repair–Deficient Colorectal Cancer: Game-Changer for Small Group of Patients

Patients with DNA mismatch repair–deficient (dMMR) metastatic colorectal cancer display a high level of microsatellite instability (MSI-H)1 and demonstrate poor chemosensitivity and shorter overall survival than patients with mismatch repair–proficient (pMMR) metastatic metastatic colorectal cancer.2 However, immune checkpoint blockade has elicited high responses in this subgroup, characterized by high tumor mutation burden.3,4 

Breast Cancer

Adjuvant Pertuzumab in HER2-Positive Breast Cancer: Value Yet to Be Demonstrated

The ASCO Post issue of June 25, 2017, did an excellent job of summarizing the results and controversy generated by the initial results of the APHINITY trial, reported at the 2017 ASCO Annual Meeting and published simultaneously online in The New England Journal of Medicine.1 With a median follow-up of about 45 months, adding 1 year of pertuzumab (Perjeta) to 1 year of trastuzumab (Herceptin) plus standard chemotherapy improved invasive disease–free survival among those entered with positive axillary nodes from 90.2% to 92.0% at 3 years and 86.7% to 89.9% at 4 years. Node-negative patients did very well in this trial regardless of whether they received pertuzumab, as they did with 12 weeks of paclitaxel and 1 year of trastuzumab in a 400-patient phase II experience,2 so most everyone concludes they do not need pertuzumab. No survival benefit is even hinted at in the first 4 years of APHINITY, and toxicity was relatively mild and manageable, with 9% experiencing severe diarrhea only during the period pertuzumab was given during chemotherapy and little excess cardiac toxicity.


More Top Stories

Gynecologic Cancers

Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial

Solid Tumors
Bladder Cancer

Durvalumab in Advanced Urothelial Carcinoma Progressing After Platinum Therapy

In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms of action, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On May 1, 2017, durvalumab (Imfinzi) was granted...


Predicting Risk of Subsequent CNS Tumors in Survivors of Childhood Cancer

As reported in the Journal of Clinical Oncology, Wang et al have developed a model for predicting risk of subsequent central nervous system (CNS) tumors in survivors of childhood cancer. Study Details In the study, matched childhood cancer survivors with (n = 82) and without (n = 228) subsequent...

Gynecologic Cancers

Simone Koole, MD, on Ovarian Cancer: Results of the OVHIPEC Trial

Lung Cancer

‘Clinically Meaningful’ Results With First-Line Osimertinib in EGFR–Positive NSCLC

OSIMERTINIB (TAGRISSO) showed encouraging results as first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) in the phase III FLAURA trial, according to results presented at the 2017 European Society for Medical Oncology (ESMO)...

Issues in Oncology

Recognizing the Importance of a Work-Life Balance in Oncology

The ASCO Post introduces this new department, Living a Full Life, in which we will share insightful narratives of oncology professionals highlighting personal aspects of these clinicians’ lives separate from the world of oncology. We also intend to open a dialogue about the challenges that today’s...

Enhancer of Zeste Homolog 2 Expression and Prognosis in Localized Renal Cell Carcinoma

As reported in the Journal of Clinical Oncology, Ho et al found that tumor-based enhancer of zeste homolog 2 (EZH2) gene or protein expression was independently predictive of prognosis in localized clear cell renal cell carcinoma. EZH2 is a chromatin remodeler implicated in the pathogenesis of...

Gynecologic Cancers

Andrew R. Clamp, PhD, on Gynecologic Cancers: Results of the ICON8 Trial

Dana-Farber Opens New Facility for Integrative Therapies

DANA-FARBER CANCER INSTITUTE has announced the opening of the new Leonard P. Zakim Center for Integrative Therapies and Healthy Living.  Increasing data have indicated that integrative therapies can help alleviate the side effects of cancer therapy. The Zakim Center, as it is commonly referred to, ...


IASLC 2017: Exercise Interventions in Advanced Lung Cancer Patients Led to Increased Functionality

Physical exercise and psychosocial interventions in patients with advanced-stage lung cancer improved functional capacity, which may be linked to quality-of-life benefits. Morten Quist, PT, PhD, MSc, of the University of Copenhagen, presented these findings at the International Association for the...